This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Brand Names
- Typhim Vi
- Generic Name
- Typhoid Vi polysaccharide vaccine
- DrugBank Accession Number
- DB10803
- Background
Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Salmonella typhi TY2 Vi polysaccharide antigen
- Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Typhoid fever caused by s. typhi •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Typherix Liquid 25 mcg / 0.5 mL Intramuscular Glaxosmithkline Inc 2000-11-27 2017-12-21 Canada 
Typhim Vi Injection, solution 25 ug/0.5mL Intramuscular A-S Medication Solutions 1994-11-28 Not applicable US 
Typhim Vi Injection, solution 25 ug/0.5mL Intramuscular Sanofi Pasteur Inc. 1994-11-28 Not applicable US Typhim Vi Solution 25 mcg/1 Intramuscular Sanofi Pasteur Limited 1995-12-31 Not applicable Canada Typhim Vi Injection, solution 25 ug/0.5mL Intramuscular A-S Medication Solutions 1994-11-28 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Vivaxim Typhoid Vi polysaccharide vaccine (25 mcg) + Hepatitis A Vaccine (160 unit) Solution; Suspension Intramuscular Sanofi Pasteur Limited 2005-11-09 2022-06-30 Canada Vivaxim Vaccine Typhoid Vi polysaccharide vaccine (25 mcg/0.5ml) + Hepatitis A Vaccine (160 i.u./0.5 ml) Suspension Intramuscular SANOFI-AVENTIS SINGAPORE PTE. LTD. 2009-07-08 Not applicable Singapore 
Categories
- ATC Codes
- J07AP03 — Typhoid, purified polysaccharide antigen
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7194H8W3KT
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Recruiting Other Coronavirus Disease 2019 (COVID‑19) / Iron Deficiency Anemia (IDA) 1 somestatus stop reason just information to hide 4 Completed Diagnostic Specific Polysaccharide Antibody Deficiency 1 somestatus stop reason just information to hide 4 Completed Prevention Disease caused by Salmonella typhi / Paratyphoid Fever 2 somestatus stop reason just information to hide 4 Not Yet Recruiting Prevention Monkeypox 1 somestatus stop reason just information to hide 4 Terminated Prevention Aging / Inflammation 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular 25 mcg/0.5ml Liquid Intramuscular 25 mcg / 0.5 mL Injection, solution Intramuscular 25 mcg/0.5ml Injection Intramuscular 0.5 ml Injection, solution Intramuscular 25 ug/0.5mL Solution Intramuscular 25 mcg/1 Solution Intramuscular; Subcutaneous 0.025 mg Injection, solution Intramuscular; Subcutaneous 25 mcg/0.5ml Injection, solution Intramuscular; Subcutaneous Injection Intramuscular; Subcutaneous 25 micrograms Injection, solution Intramuscular 0.025 mg Injection Intramuscular; Subcutaneous 0.025 mg Injection, suspension Intramuscular 0.5 mL Solution; suspension Intramuscular Suspension Intramuscular 160 i.u./0.5 ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at September 12, 2024 23:22